Yahoo Web Search

Search results

1. • Q1 2024 Exscientia PLC Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 12 hours ago

     And for the first time announcing our plans for our MALT1 inhibitor, XS73565 or 565 as a potential treatment for B-cell lymphomas, including chronic lymphocytic< ...

2. • 

     Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion

     Zacks via Yahoo Finance· 6 days ago

     Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...

3. • Exercise bouts could improve efficacy of cancer drug

     Medical Xpress· 21 hours ago

     Researchers at the Universities of Birmingham and Bath found that a bout of exercise increased the number of anti-cancer immune cells—called natural killer cells—and that these cells were around ...

4. • 

     Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

     Zacks via Yahoo Finance· 6 days ago

     The therapy was also granted accelerated approval for the treatment of relapsed or refractory ...

5. • Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration...

     Morningstar· 7 days ago

     Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma 95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical

6. • Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma

     Morningstar· 6 days ago

     Breyanzi, which was already approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma after at least one line of therapy and for relapsed or refractory ...

7. • Q1 2024 Bio Path Holdings Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 6 days ago

     Venetoclax has shown activity against the [anti-up total] protein Bcl-2 and works by neutralizing the protein's BH-3 domain. It is an approved treatment for chronic

8. • 

     Keeping CAR T Cells Sharp

     The Scientist· 1 day ago

     Chimeric antigen receptor (CAR) T cells have a tough job. Engineered with a receptor that recognizes molecules decorating the surface of cancer cells,...

9. • The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below...

     Nature· 5 days ago

     Detection of measurable residual disease (MRD) in hematological malignancies is crucial for prognostication and treatment decisions. Real-time quantitative PCR (RQ-PCR), which targets immunoglobulin ...

10. • 

      GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market

      NewMediaWire via Yahoo Finance· 5 days ago

      ATLANTA, GA - (NewMediaWire) - May 17, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...